新型支架移植物治疗Stanford A型主动脉夹层的早中期结果
这项前瞻性、多中心、单臂研究纳入53例高危开放手术的Stanford A型主动脉夹层患者,评估新型支架移植物的可行性与有效性。主要终点为1个月主动脉相关死亡或再干预。结果技术成功率100%,主动脉相关死亡率1.9%,早中期结果满意。
要点
- 新型支架移植物经股动脉置入技术成功率100%。
- 1个月主动脉相关死亡率为1.9%(1/53)。
- 6例(11.3%)因并发症需开放手术。
核心结论
- 新型支架移植物治疗高危Stanford A型主动脉夹层的早中期结果满意,技术成功率100%,主动脉相关死亡率1.9%。
研究设计与样本
- 前瞻性、多中心、单臂研究,纳入53例高危开放主动脉修复的Stanford A型主动脉夹层患者。
主要发现
- 全因死亡率3.8%(2/53),主动脉相关死亡率1.9%(1/53)。
- 6例(11.3%)需开放手术,原因包括左心室破裂1例、主动脉夹层逆行进展3例、严重Ia型内漏2例。
- 轻度Ia型内漏1例,脑梗死1例。
- 中位随访6个月(范围1-24个月)。
关键数值与推荐
- 主要终点为1个月主动脉相关死亡或再干预。
- 次要终点包括1、6、12个月Ia和III型内漏及主要不良心脑血管事件。
临床怎么用
- 对于高危开放手术的Stanford A型主动脉夹层患者,新型支架移植物可作为可行治疗选择,但需注意内漏和逆行进展风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: The objective of this study was to assess the feasibility and effectiveness of the novel stented graft in treating Stanford type A aortic dissection (TAAD). METHODS: This research was a prospective, multicentre, single-arm study that enrolled patients with Stanford TAAD at high risk for open aortic repair. Primary end-points included aorta-related mortality or reintervention at 1 month. Secondary end-points comprised type Ia and III endoleak, major adverse cardiovascular and cerebrovascular events at 1 month, 6 months, and 12 months. RESULTS: Fifty-three patients were enrolled with a mean age of 63.3 years (range 30-81), of whom 44 (83.0%) were male. Forty-six (86.8%) patients presented with retrograde Stanford TAAD, while the remainder had DeBakey type II aortic dissection. Forty-eight patients (90.6%) were in the acute phase. Carotid-to-subclavian artery bypass was performed in 17(32.1%) patients. The stented graft was successfully delivered via the femoral artery in all cases. Follow-up occurred at 1 month, 6 months, and 12 months. The median follow-up was 6 months (range 1-24). The all-cause mortality was 3.8% (2/53) and the aorta-related mortality was 1.9% (1/53). Six(11.3%) patients required open surgery due to left ventricular rupture (1 patient), retrograde progression of aortic dissection (3 patients), and severe type Ia endoleak (2 patients). Mild type Ia endoleak was observed in 1 patient and 1 patient suffered from cerebral infarction. CONCLUSIONS: The early and midterm results of the first-in-man evaluation of the new stented graft for Stanford TAAD were satisfactory, achieving 100% technical success and 1.9% aorta-related mortality. CLINICAL TRIAL REGISTRATION NUMBER: This clinical trial was registered in the Chinese Clinical Trial Registry under the identifier ChiCTR2200057706 (Chinese Clinical Trial Register (ChiCTR)-The world health organization international clinical trials registered organization registered platform).
引用
- Yang J, Hu J, Yan Y, et al. Early and Midterm Results of a Novel Stented Graft for Patients with Stanford Type A Aortic Dissection. Eur J Cardiothorac Surg. 2025. PMID: 41234038. doi:10.1093/ejcts/ezaf401
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。